CTOs on the Move

Omasky Group

www.omanskygroup.com

 
Omasky Group is a Hinesburg, VT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Stop Heart Attack Dot Com

Stop Heart Attack Dot Com is a Birmingham, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kedrion

Kedrion Biopharma develops and produces plasma-derived therapies, making them available to meet patients` needs the world over. We collect and fractionate blood plasma for the development, production and distribution of plasma derivatives used in the treatment of patients suffering from rare and chronic conditions such as hemophilia and immune system deficiencies. A corporation is not a person, but a corporation is run by people and it affects people. And Kedrion`s business is people. The very nature of our enterprise is to help people live more full and healthy lives. This commitment extends to how we conduct our business, that is, in ways that are consistent with our mission: to build bridges that.benefit people. Long a major player in the plasma derivatives sector in Italy, as partner with the Italian Health System, Kedrion has now become an international participant in the industry with a market presence in about 100 countries. We have plants in Italy, Hungary and the United States and plasma collection centers in the U.S., Germany and Hungary. Kedrion looks forward to continued expansion and the wider sharing of its experience, know-how and technology to foster self-sufficiency of plasma-derived therapies worldwide and to bring healthier and less restricted lives to people suffering from rare disorders. Kedrion Biopharma produces wealth for investors, employees and for the local community, consistent with its own vision and values: responsibility, transparency, confidence in and respect for people. Our goal is to build a diverse and professional workforce, providing job opportunities for talented external candidates as well as internal employees who aim to grow with us. Because our work includes so many interests and skills – from Research to Sales; Plasma Collection to Production – there are abundant possibilities for learning and growth. Kedrion Biopharma builds bridges: from donors to patients, from plasma to therapies, from challenge to hope.

Octave

Octave Health is the nation`s first practice supporting all aspects of emotional well-being.

AcelRx

AcelRx Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. The Company`s product candidates, DSUVIA™ (known as ARX-04 outside of the United States) and ZALVISO®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. DSUVIA is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. The Phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. In clinical studies, DSUVIA demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and vomiting. A New Drug Application (NDA) was filed with the FDA in December 2016. ZALVISO is designed to deliver sublingual tablets containing 15 mcg sufentanil via a novel hand-held, pre-programmed, patient-controlled analgesia system. Three Phase 3 clinical trials have been completed in patients who had undergone major abdominal or orthopedic surgeries. A fourth study (IAP312) is underway to further evaluate the overall performance of the ZALVISO System in post-surgical patients. ZALVISO is currently approved by the European Commission for the management of acute moderate-to-severe post-operative pain in adult patients in a hospital setting, and is marketed by Grünenthal Group, AcelRx`s licensee in Europe and Australia. In the United States and other geographies, ZALVISO remains an investigational product.

Sciformix

We are a leading Scientific Process Organization (SPO), providing scientific knowledge-based services to biopharmaceutical, generic pharmaceutical, consumer product, medical device, contract research and healthcare companies. We partner with our clients through the entire drug development cycle to provide a broad range of services from study design to post marketing surveillance and commercialization support. We deliver consistent quality and compliance across the services by employing scientific rigor in combination with streamlined process, optimal technology and efficient people practices.